{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone+2+mg",
    "query": {
      "intervention": "Risperidone 2 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 80,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Risperidone+2+mg&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-18T08:34:36.065Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04624243",
      "title": "Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Elpipodect",
          "type": "DRUG"
        },
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Placebo to MK-8189",
          "type": "DRUG"
        },
        {
          "name": "Placebo to risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 499,
      "start_date": "2020-12-15",
      "completion_date": "2024-06-21",
      "has_results": true,
      "last_update_posted_date": "2026-04-29",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 35,
      "location_summary": "Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 27 more",
      "locations": [
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Bellflower",
          "state": "California"
        },
        {
          "city": "Culver City",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04624243"
    },
    {
      "nct_id": "NCT00225498",
      "title": "Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "ziprasidone vs risperidone or olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwell Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 35,
      "start_date": "2002-06",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2015-09-10",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00225498"
    },
    {
      "nct_id": "NCT04201834",
      "title": "Risperidone for the Treatment of Huntington's Disease Involuntary Movements",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Huntington Disease",
        "Chorea"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "BioStamp nPoint device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "University of Rochester",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 6,
      "start_date": "2020-08-13",
      "completion_date": "2023-12-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-21",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201834"
    },
    {
      "nct_id": "NCT01786239",
      "title": "Omega-3 Dietary Supplements in Schizophrenia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia",
        "Schizophreniform Disorder",
        "Schizoaffective Disorder",
        "Bipolar Disorder",
        "Psychosis NOS"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Omega-3 capsules",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Delbert Robinson",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "15 Years to 40 Years"
      },
      "enrollment_count": 50,
      "start_date": "2013-05",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Glen Oaks, New York",
      "locations": [
        {
          "city": "Glen Oaks",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01786239"
    },
    {
      "nct_id": "NCT01222975",
      "title": "Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fasting Conditions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ranbaxy Laboratories Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2004-10",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2010-10-18",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01222975"
    },
    {
      "nct_id": "NCT03565068",
      "title": "A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "MK-8189",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Background AAP Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 75,
      "start_date": "2018-06-20",
      "completion_date": "2020-04-03",
      "has_results": true,
      "last_update_posted_date": "2021-03-29",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03565068"
    },
    {
      "nct_id": "NCT01234454",
      "title": "Atypical Antipsychotic Treatment Effect On Brain Function In Schizophrenia Measured By FMRI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone",
          "type": "DRUG"
        },
        {
          "name": "Olanzapine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of North Carolina, Chapel Hill",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 34,
      "start_date": "2002-01",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01234454"
    },
    {
      "nct_id": "NCT00722176",
      "title": "Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "BL-1020",
          "type": "DRUG"
        },
        {
          "name": "BL-1020 10-30 mg",
          "type": "DRUG"
        },
        {
          "name": "risperidone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioLineRx, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 220,
      "start_date": "2008-06",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-06-29",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00722176"
    },
    {
      "nct_id": "NCT00167154",
      "title": "Risperidone and Suicidality in Major Depressive Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Risperidone and placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "19 Years to 60 Years"
      },
      "enrollment_count": 30,
      "start_date": "2004-06",
      "completion_date": "2008-08",
      "has_results": false,
      "last_update_posted_date": "2021-06-10",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167154"
    },
    {
      "nct_id": "NCT00667745",
      "title": "Effectiveness of Lithium Plus Optimized Medication in Treating People With Bipolar Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bipolar Disorder"
      ],
      "interventions": [
        {
          "name": "Lithium Carbonate",
          "type": "DRUG"
        },
        {
          "name": "Optimized Treatment (OPT)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Mental Health (NIMH)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 283,
      "start_date": "2008-04",
      "completion_date": "2010-03",
      "has_results": true,
      "last_update_posted_date": "2018-02-13",
      "last_synced_at": "2026-09-18T08:34:36.065Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Boston, Massachusetts • Cleveland, Ohio + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00667745"
    }
  ]
}